OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Organization: Washington University in St. Louis

4 Projects | 4 Researchers | $4,224,528 Invested

2026

Washington University in St. Louis

Timothy Miller, MD, PhD

Optimizing a Gene-Targeted Therapeutic to Enhance TBK1 Expression in Genetic FTD

  • Funding Amount: $348,007
  • Organization Type:
  • Program: Drug Discovery
  • Target: Other
  • Status: Active

2020

Washington University in St. Louis

Miranda Orr, PhD

Phase II Clinical Trial to Evaluate the Safety and Feasibily of Senolytic Therapy in Alzheimer's Disease

  • Funding Amount: $3,439,379
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Tau
  • Status: Active

2019

Washington University in St. Louis

Laura Ibanez, PhD

Plasma Cell-Free RNA as Alzheimer's Disease non-invasive biomarker

  • Funding Amount: $280,152
  • Organization Type: Academic/Nonprofit
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Closed

2012

Washington University in St. Louis

Nigel Cairns, PhD, FRCPath

Restoring progranulin in frontotemporal disease

  • Funding Amount: $156,990
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Other
  • Status: Closed